4DMT Reveals Pricing for $100 Million Common Stock and Pre-Funded Warrant Offering

Offering Announcement: 4D Molecular Therapeutics has priced an underwritten offering of 8,385,809 shares of common stock at $10.51 per share, along with pre-funded warrants for 1,128,949 shares, aiming to raise approximately $100 million before expenses.

Use of Proceeds: The proceeds from the offering will support the company's development of disease-targeted therapeutics, including its lead product candidate, 4D-150, which is in Phase 3 development for treating wet age-related macular degeneration.

Management and Closing: The offering is managed by Leerink Partners, Evercore ISI, and Cantor Fitzgerald, with the expected closing date on November 7, 2025, pending customary conditions.

Forward-Looking Statements: The press release includes forward-looking statements regarding the offering and the company's future performance, highlighting potential risks and uncertainties that could affect outcomes.